Treatment for sickle cell disease, the most common inherited blood disorder in Kenya, has been approved for use in England for older children and adults with a severe form of the disease.The treatment ...
NHS approves £1.65m gene therapy for sickle cell disease, offering a potential cure. A milestone for patients, especially in ...
In this article, we explore the experiences of sickle cell patients in emergency care and the ways they can advocate for themselves ...
Antibodies are also known as immunoglobulins (Ig). "Immuno" describes immunity and "globulin" describes protein. They are produced by B cells, a specific type of white blood cell (WBC) that originates ...
But for a brief moment on a recent December morning, Wedam, 19, who has sickle cell disease ... the procedure was successful. But antibodies in Wedam’s bloodstream prevented the same cure ...
HBV and HCV infections are more likely to occur in children with sickle cell disease because of the need for multiple blood transfusions. This pilot study was intended to evaluate the frequency of ...
HBV and HCV infections are more likely to occur in children with sickle cell disease because of the need for multiple blood transfusions. This pilot study was intended to evaluate the frequency of ...
According to precedent and due to his status, Yoon will probably be assigned a solitary cell, likely bigger and better appointed than the standard 6.56 square metre (71 square feet) single cells.
Beam Therapeutics has announced significant progress in its clinical trials and portfolio regarding precision genetic medicines, particularly in the area of sickle cell disease (SCD). Over 40 ...
T-cell engagers have been hot property in recent months, so it’s only right that one the biggest deals to kick off the J.P. Morgan Healthcare conference should see AbbVie expanding its interest ...
Listen to more stories on the Noa app. The human cell is a miserable thing to study. Tens of trillions of them exist in the body, forming an enormous and intricate network that governs every ...